Clinical trials: Pancreas Diseases
Chronic Pancreatitis
Fatigue, Psychological Comorbidity and Quality of Life Among Patients With Chronic Pancreatitis in China.
This study will investigate the status of fatigue, psychological comorbidity and quality of life among patients with chronic pancreatitis in China and analyze their influencing factors.
- Trial name
- NCT05489003
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Changhai Hospital
Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages.
- Trial name
- ResCPa (NCT07153289)
- Testing
- CD318-CAR-T cells
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Pancreatic Cancer
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer.
- Trial name
- NCT00276744
- Testing
- cetuximab, capecitabine, docetaxel
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes
The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes
The overall aim of the study is to evaluate the performance of Artificial Pancreas or Closed Loop Glucose-Sensing Insulin-Delivery system in comparison to current best available technology represented by Sensor Augmented Pump…
- Trial name
- NCT02040571
- Testing
- Closed Loop, Open Loop
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- St Vincent's Hospital Melbourne
Pancreas Adenocarcinoma, Pancreas Cancer
PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
- Trial name
- PaCaReg (NCT04099134)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Lymphoma, Nasopharyngeal Cancer
Applying PET/MR in Oncology - a Prospective Project
Cancer is a global health issue. According to the World Health Organization, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.
- Conditions
- Lymphoma, Nasopharyngeal Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT04158414
- Testing
- PET/MR scan
- Volunteers
- 500 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100…
- Trial name
- NCT05743244
- Testing
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pancreas Cancer
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer
1. To study the expression pattern of Integrin alpha 2b (ITGA2b) and Selectin P (SELP) genes of Tumor educated platelets in pancreatic and biliary tree cancer and its diagnostic value. 2.
- Trial name
- NCT05493878
- Testing
- mRNA expression
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Assiut University
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cystic Fibrosis
Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis
The purpose of this protocol is to begin an exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation. The exercise program will begin during the hospital stay.
- Trial name
- NCT04075864
- Testing
- Behavioral Counseling and Exercise
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cysts
Registry and Fluid Banking of Pancreatic Cystic Lesions
The purpose of this study is to follow patients, who have small mucinous cysts in the pancreas, prospectively over a 5-year period.
- Trial name
- NCT01769534
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Pancreatic Cancer
Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer
Aim of this study is to evaluate if low-dose radiotherapy (LDR) can intensify local effect of a chemotherapy regimen with Gem-based doublets administered sequentially with stereotactic body radiotherapy (SBRT) and to assess the…
- Trial name
- ORCHESTRATE (NCT02416609)
- Testing
- LDR, Gem-based doublets, SBRT
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Pancreatic Neoplasms
A Study for Participants With Pancreatic Cancer
The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study.
- Trial name
- NCT00839332
- Testing
- LY2603618, Gemcitabine
- Where
- 30 sites in United States, Germany and 4 more
- Volunteers
- 157 people
- Sponsor
- Eli Lilly and Company
Abdominal Compartment Syndrome, Pancreatitis,Acute Necrotizing
Fasciotens to Treat an Open Abdomen - a Prospective Cohort Study
The open abdomen can occur as a result of various diseases. After infections of the abdomen, compartment syndromes or traumata, it is essential for survival (1). This condition of the open abdomen lasts from days to months.
- Conditions
- Abdominal Compartment Syndrome, Pancreatitis,Acute Necrotizing, Intraabdominal Hypertension, Peritonitis
- Trial name
- Fasciotens (NCT04033614)
- Testing
- Fasciotens-Abdomen
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- RWTH Aachen University
Pancreatic Cancer
Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities
Pancreatic cancer is the 5th leading cause of cancer death and the worst prognostic cancer in the world. This is due to high recurrent rate after surgical resection and poor response to chemotherapy and radiotherapy.
- Trial name
- NCT02887599
- Testing
- Blood collection
- Where
- South Korea
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Pancreatic Cancer
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00126633
- Testing
- bevacizumab, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Francisco
IPMN, IPMN, Pancreatic
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
- Trial name
- NCT04207944
- Testing
- Sulindac 400 MG
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.